Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Kiniksa Pharmaceuticals International filings provide 3 years of Finished Goods readings, the most recent being $12.9 million for Q4 2023.

  • On a quarterly basis, Finished Goods fell 15.85% to $12.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $12.9 million, a 15.85% decrease, with the full-year FY2023 number at $12.9 million, down 15.85% from a year prior.
  • Finished Goods hit $12.9 million in Q4 2023 for Kiniksa Pharmaceuticals International, up from $12.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $19.9 million in Q2 2022 to a low of $1.4 million in Q3 2021.
  • Median Finished Goods over the past 3 years was $12.5 million (2023), compared with a mean of $10.4 million.
  • Biggest five-year swings in Finished Goods: soared 927.48% in 2022 and later fell 24.22% in 2023.
  • Kiniksa Pharmaceuticals International's Finished Goods stood at $3.7 million in 2021, then skyrocketed by 315.97% to $15.3 million in 2022, then fell by 15.85% to $12.9 million in 2023.
  • The last three reported values for Finished Goods were $12.9 million (Q4 2023), $12.2 million (Q3 2023), and $17.3 million (Q2 2023) per Business Quant data.